Raymond James reiterates Tvardi Therapeutics stock rating on HCC data
Raymond James reiterated an Outperform rating and $10.00 price target for Tvardi Therapeutics (TVRD) after Q3 2026 earnings, citing encouraging data for TTI-101 in HCC and TTI-109's tolerability. The stock is down 73% YTD but appears undervalued, with upward earnings revisions. The HCC readout is delayed to Q1 2027. Other analysts also initiated coverage with buy ratings and price targets ranging from $8.00 to $14.00.
How this was made
The 30-second read
Why it matters
The reiteration of an Outperform rating and a $10 target may attract short‑term buying interest, but the core fundamentals have not changed.
Market read
A modest analyst upgrade for a micro‑cap biotech; limited trading relevance beyond the stock itself.
What to watch
Financing risk for TTI‑109 and the need for additional capital could constrain upside.
Background
The article is an analyst rating update that repeats data from Tvardi's recent earnings release and trial updates.
Ticker impact
Raymond James reiterated an Outperform rating and $10 price target for Tvardi Therapeutics after its Q3 2026 earnings, citing encouraging trial data.
likely upward pressure as investors price in the higher target and trial optimism
The rating and target are new analyst actions, but the underlying earnings and trial data were already public, limiting impact.
Market effects
Minimal; reinforces positive sentiment in the biotech/oncology space.
US biotech sector may see slight uptick.
Limited to investors tracking small‑cap biotech stocks.
Counterpoint
The stock remains highly volatile and heavily discounted; the upgrade may be premature.
Key entities
- AnalystRaymond James
Equity research firm providing the rating and price target.
- CompanyTvardi Therapeutics Inc
Biotech firm developing STAT3 inhibitors for HCC and ulcerative colitis.

